CAT

773.92

+2.11%↑

314.64

+0.61%↑

RTX

199.99

-0.65%↓

GEV.US

801.92

-1.81%↓

242.96

+1.55%↑

CAT

773.92

+2.11%↑

314.64

+0.61%↑

RTX

199.99

-0.65%↓

GEV.US

801.92

-1.81%↓

242.96

+1.55%↑

CAT

773.92

+2.11%↑

314.64

+0.61%↑

RTX

199.99

-0.65%↓

GEV.US

801.92

-1.81%↓

242.96

+1.55%↑

CAT

773.92

+2.11%↑

314.64

+0.61%↑

RTX

199.99

-0.65%↓

GEV.US

801.92

-1.81%↓

242.96

+1.55%↑

CAT

773.92

+2.11%↑

314.64

+0.61%↑

RTX

199.99

-0.65%↓

GEV.US

801.92

-1.81%↓

242.96

+1.55%↑

Home・Akciju saraksts・Cross Country Healthcare Inc

Cross Country Healthcare Inc

Atvērts

SektorsRūpniecība

8.03 1.52

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.98

Max

8.12

Galvenie mērījumi
By Trading Economics
Ienākumi	1.9M -4.8M
Pārdošana	-24M 250M
EPS	0.03
Peļņas marža	-1.909
Darbinieki	9,605
EBITDA	86K -993K

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+22.9% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-124M 276M
Iepriekšējā atvēršanas cena	6.51
Iepriekšējā slēgšanas cena	8.03

Ziņu noskaņojums

By Acuity

41%

59%

148 / 406 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

13.52 / 13.92 Atbalsts un pretestība

Cross Country Healthcare Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. febr. 23:21 UTC

Iegādes, apvienošanās, pārņemšana

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026. g. 15. febr. 23:45 UTC

Tirgus saruna

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026. g. 15. febr. 23:40 UTC

Tirgus saruna

Gold Falls on Possible Position Adjustments -- Market Talk

2026. g. 15. febr. 23:06 UTC

Peļņas

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026. g. 15. febr. 23:04 UTC

Peļņas

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026. g. 15. febr. 23:04 UTC

Peļņas

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026. g. 15. febr. 23:01 UTC

Peļņas

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026. g. 15. febr. 23:01 UTC

Peļņas

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026. g. 15. febr. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026. g. 15. febr. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026. g. 15. febr. 22:52 UTC

Iegādes, apvienošanās, pārņemšana

Qube Shareholders to Receive A$5.20/Share in Cash

2026. g. 15. febr. 22:52 UTC

Iegādes, apvienošanās, pārņemšana

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026. g. 15. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO Tania Archibald Speaking on a Call With Media

2026. g. 15. febr. 22:17 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

2026. g. 15. febr. 22:16 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

2026. g. 15. febr. 22:14 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

2026. g. 15. febr. 22:14 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

2026. g. 15. febr. 20:48 UTC

Peļņas

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026. g. 15. febr. 20:47 UTC

Peļņas

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026. g. 15. febr. 20:46 UTC

Peļņas

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026. g. 15. febr. 20:45 UTC

Peļņas

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026. g. 15. febr. 20:44 UTC

Peļņas

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026. g. 15. febr. 20:44 UTC

Peļņas

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026. g. 15. febr. 20:43 UTC

Peļņas

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026. g. 15. febr. 20:42 UTC

Peļņas

BlueScope Net Debt A$2.2 Million at Dec. 31

2026. g. 15. febr. 20:42 UTC

Peļņas

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026. g. 15. febr. 20:41 UTC

Peļņas

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026. g. 15. febr. 20:40 UTC

Peļņas

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026. g. 15. febr. 20:40 UTC

Peļņas

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026. g. 15. febr. 20:39 UTC

Peļņas

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Salīdzinājums

Cenas izmaiņa

Cross Country Healthcare Inc Prognoze

Cenas mērķis

By TipRanks

22.9% augšup

Prognoze 12 mēnešiem

Vidējais 9.93 USD 22.9%

Augstākais 11 USD

Zemākais 8.65 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cross Country Healthcare Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cross Country Healthcare Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

13.52 / 13.92Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Noskaņojums

By Acuity

148 / 406 Rangs Rūpniecība

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cross Country Healthcare Inc

Cross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States. The company's Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel and local nurse and, allied professionals; temporary placement of healthcare leaders within nursing, allied, physician, and human resources; vendor neutral and managed services programs; education healthcare services; in-home care services; and outsourcing services. It also offers staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term contract assignments, as well as workforce solutions, including MSP, VMS, in- home care, education healthcare, RPO, project management, and other outsourcing and consultative services. This segment provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. It serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and other healthcare providers under the Cross Country brand. Its Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants under the Cross Country Locums brand on temporary assignments. It serves various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.